Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Relay TherapeuticsRLAY +0.40%46 6-1 Month Momentum % is 127.07% as of Aug. 13, 2026. GuruFocus rates RLAY with a GF Score™ of 46/100 and a GF Value™ of $3.80 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 1,383 Biotechnology companies, Relay Therapeutics ranks better than 97.11% on this metric.
6-1 Month Momentum % is the total return of the stock from 6-month ago to 1-month ago. As of today (2026-08-13), Relay Therapeutics's 6-1 Month Momentum % is 127.07%.
The industry rank for Relay Therapeutics's 6-1 Month Momentum % or its related term are showing as below:
RLAY's 6-1 Month Momentum % is ranked better than 97.11% of 1383
companies
in the Biotechnology industry
Industry Median: -10.68
vs RLAY: 127.07
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 6-1 Month Momentum % measures the total return to a stock over the past six months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Relay Therapeutics 6-1 Month Momentum % Related Terms
RLAY vs CELC, VKTX, DYN: 6-1 Month Momentum % Comparison
For the Biotechnology subindustry, Relay Therapeutics's 6-1 Month Momentum %, along with its competitors' market caps and 6-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Relay Therapeutics 6-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Relay Therapeutics's 6-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Relay Therapeutics's 6-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Relay Therapeutics (RLAY) has a 6-1 Month Momentum % of 127.07% as of Aug. 13, 2026. 6-1 Month Momentum measures the total return of the stock from 6-month ago to 1-month ago. View historical data on Relay Therapeutics and its competitors. According to the industry distribution chart, Relay Therapeutics ranks #40 out of 1383 companies in the Biotechnology industry, placing it in the top 2.9%.
Is Relay Therapeutics' 6-1 Month Momentum % too high?
Relay Therapeutics' current 6-1 Month Momentum % is 127.07%. Based on the distribution chart, Relay Therapeutics ranks #40 out of 1383 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Relay Therapeutics has a GF Score™ of 46/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Relay Therapeutics' 6-1 Month Momentum % compare to CELC and VKTX?
According to the Biotechnology industry distribution chart, Relay Therapeutics ranks #40 out of 1383 companies for 6-1 Month Momentum %. This places Relay Therapeutics in the top 3% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 6-1 Month Momentum % for a Biotechnology company?
A good 6-1 Month Momentum % depends on the Biotechnology industry context. However, 6-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 6-1 Month Momentum % mean?
A high 6-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 6-1 Month Momentum measures the total return of the stock from 6-month ago to 1-month ago. View historical data on Relay Therapeutics and its competitors. Relay Therapeutics's current 6-1 Month Momentum % is 127.07%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Relay Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Relay Therapeutics (RLAY) is currently considered Significantly Overvalued. The stock's GF Value™ is $3.80, compared to a current price of $20.08 — trading 428.4% above its estimated fair value. The current 6-1 Month Momentum % is 127.07%. Relay Therapeutics' overall GF Score™ is 46/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 6-1 Month Momentum % calculated?
6-1 Month Momentum % is calculated from a company's financial statements. For Relay Therapeutics (RLAY), the current 6-1 Month Momentum % is 127.07% as of Aug. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Relay Therapeutics (RLAY) Overvalued in 2026?
Based on GuruFocus' analysis, Relay Therapeutics stock appears to be overvalued.
The current stock price of $20.08 is trading 428.4% above its estimated GF Value™ of $3.80.
GuruFocus considers Relay Therapeutics to be Significantly Overvalued.
Key valuation signals for RLAY:
6-1 Month Momentum %: 127.07%
GF Value™: $3.80 vs. price of $20.08 (428.4% above fair value)
No single metric tells the full story. See the RLAY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process and bringing life-changing therapies to patients. The Dynamo platform of the company integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-8186, RLY-2608, RLY-4008 and others.
46GF Score
Get the complete analysis for RLAY
6-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RLAY has been successfully added to your 
